OAB and Incontinence

Keith Xavier, MD, discusses the role of Altaviva in treating men with overactive bladder and urge urinary incontinence, including patient selection, clinical considerations, and its place among third-line therapies.

The next-generation implant is designed to extend the implant longevity from 10 years to 15 years.

The phase 2 trial will assess the safety and efficacy of ViXe, a product designed to deliver botulinum toxin directly into the bladder wall.

In this interview, Brett Trockman, MD, FACS, details how shifting guideline recommendations and expanding treatment options are allowing for more personalized approaches to sacral neuromodulation.

The device will be available over the counter in the US, with anticipated availability beginning in April 2026.

At SUFU 2026, 24-month data from the TITAN 2 trial showed that the Altaviva ITNM system provided sustained reductions in urgency urinary incontinence episodes, durable quality-of-life improvements, and a favorable safety profile through 24 months.

When symptoms appear tied to the menstrual cycle, pharmacologic options can be used as short-term support.

Aleece Fosnight, MSPAS, PA-C, highlights pattern recognition as a cornerstone of diagnosis, encouraging clinicians to closely examine how urinary symptoms fluctuate across the menstrual cycle.

Aleece Fosnight, MSPAS, PA-C, emphasizes that timing is one of the most valuable diagnostic clues.